UnitedHealth Group Incorporated shares are in focus as the company prepares to report its second-quarter earnings before the market opens on Thursday. The stock is currently experiencing downward pressure, trading 2.20% lower at $415.85 at the time of publication. Investors are awaiting quarterly results, with analysts anticipating earnings per share of $4.85 and revenue of $110.77 billion. The company has beaten EPS estimates in three consecutive quarters, including the most recent period where it reported EPS of $7.23 against estimates of $6.56 and revenue of $111.72 billion against estimates of $109.57 billion.

Analyst Consensus and Recent Actions

The stock carries a Buy rating with an average price target of $432.63. Several analysts have recently adjusted their price targets ahead of the earnings release. TD Cowen maintained a Hold rating and raised its target to $430.00. Truist Securities maintained a Buy rating and raised its target to $480.00. Keybanc maintained an Overweight rating and raised its target to $475.00.

Key Metrics to Watch

Investors should monitor Medicare Advantage membership trends and pricing commentary related to the recent payment hike, which serves as a macro tailwind for the sector. Additionally, growth in Optum's services and pharmacy benefit businesses will be scrutinized to offset any potential flat-to-down consolidated revenue.

HSBC analyst Sidharth Sahoo has maintained a Hold rating on UnitedHealth Group while raising the stock's price target. The new target of $380 represents an increase from the previous $300, reflecting an updated valuation of the healthcare giant's prospects.

Rating and Target Details

The adjustment to the price target follows a review of UnitedHealth's market position. The following table summarizes the revised guidance provided by HSBC:

This revision signals the analyst's adjusted outlook on the company's future earnings and strategic direction within the healthcare sector.